期刊文献+

阿奇霉素分散片人体药动学及生物等效性研究 被引量:2

Study on Pharmacokinetics and Bioequivalence of Azithromycin Dispersible Tablets in Healthy Volunteers
原文传递
导出
摘要 目的研究阿奇霉素分散片健康人体的药动学与生物等效性。方法20名男性健康志愿者随机交叉口服阿奇霉素分散片受试制剂和参比制剂各500mg,采用高效液相色谱-质谱法(LC-MS)测定血药浓度。以DAS2.0软件计算其药动学参数,考察其生物等效性。结果受试制剂和参比制剂阿奇霉素AUC0-168分别为(8.98±1.74)μg·h·mL-1和(8.75±1.60)μg·h·mL-1,Cmax分别为(0.81±0.14)μg·mL-1和(0.80±0.14)μg·mL-1,t1/2分别为(48.16±11.10)h和(51.1±7.60)h,Tmax分别为(1.80±0.86)h和(1.82±0.92)h,受试制剂相对于参比制剂的生物利用度为(103.4±20.2)%。结论阿奇霉素分散片受试制剂和参比制剂具有生物等效性。 OBJETIVE To study the pharmacokinetics and bioequivalence of azithromycin dispersible tablets in healthy volunteers.METHODS A single oral dose of 500 mg test or reference formulations was given to 20 male healthy volunteers in a randomized cross-over design.The concentration of azithromycin in plasma was determined by HPLC-MS.Pharmacokinetic parameters and relative bioavailability were calculated by DAS 2.0 software.RESULTS The main pharmacokinetic parameters of test and reference azithromycin were as the followings:AUC0-168(8.98±1.74) μg·h·mL^-1 and(8.75±1.60) μg·h·mL^-1;Cmax(0.81±0.14) μg·mL^-1 and(0.80±0.14) μg·h·mL^-1;t1/2(48.16±11.10) h and(51.1±7.60) h;Tmax(1.80±0.86) h and(1.82±0.92) h.The relative bioavailability of test to reference preparation was(103.4±20.2)%.CONCLUSION The test and reference formulations were bioequivalent.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2010年第1期40-42,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 阿奇霉素 药动学 生物等效性 高效液相色谱-质谱法 azithromycin pharmacokinetics bioequivalence LC-MS
  • 相关文献

参考文献4

二级参考文献16

  • 1唐欣,钱平利,温泉,刘泽源.阿奇霉素片剂的生物等效性研究[J].中国药物应用与监测,2005,2(2):50-52. 被引量:6
  • 2户塚恭一,万献尧,毕丽岩.阿奇霉素[J].日本医学介绍,2004,25(7):297-299. 被引量:12
  • 3吕昭云,岳天辉,李淑斌,陈大为.国产阿奇霉素的临床疗效及安全性[J].中国医院药学杂志,2004,24(5):305-307. 被引量:62
  • 4兰红梅,丁黎,简龙海,黄鑫,沈建平,张银娣.HPLC-MS法测定人血浆中阿奇霉素浓度及其药动学[J].中国临床药学杂志,2005,14(1):26-30. 被引量:18
  • 5张菁,郭蓓宁,张婴元.阿奇霉素临床药代动力学研究[J].中国临床药理学杂志,1996,12(2):89-92. 被引量:37
  • 6郭祖超.医用数理统计方法[M].北京:人民卫生出版社,1988..
  • 7Yang J, Wang GJ, Liu XQ, et al. Development of hioavailability program package 2.0[J]. Chin J Clin Pharmacol,2003,19(2):125.
  • 8Najib NM.Idkaidek N,Ghanem IE,et al.Bioequivalence assessment of azomycin(Julphar,UAE)as compared to zithromax(Pfizer.USA)-two brands of azithromycin-in healthy human volunteers[J].Biopharm Drug Dispos,2001,22(1):15.
  • 9Fouda HG. Schneider RP. Quantitative determination of the antibiotic aznthromycin in human serum by high-performance liquid chromatography (HPLC)-atmospheric pressure chemical ionization mass spectrometry:eorrelation with a standard HPLC-eleetroehemieal method [J]. Ther DrugMonit, 1995,17(2) : 179.
  • 10Gulati R,Tripathi CD,Chandra D.Comparative bioavailability of two formulatiorts of azithromyein[J] .J Assoc. Physicians India.2000,48(6) :606.

共引文献33

同被引文献19

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部